Skip to main content

Inflammatory Response

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Galvani Bioelectronics
1 program
Stimulator deviceN/A1 trial
Active Trials
NCT04171011Completed14Est. Oct 2020
Philips
PhilipsNetherlands - Amsterdam
1 program
Pneumovax 23PHASE_11 trial
Active Trials
NCT05346302Completed249Est. Dec 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PhilipsPneumovax 23
Galvani BioelectronicsStimulator device

Clinical Trials (2)

Total enrollment: 263 patients across 2 trials

NCT05346302PhilipsPneumovax 23

Persistent Readiness Through Early Prediction Immunization Study

Start: Feb 2022Est. completion: Dec 2022249 patients
Phase 1Completed

Nerve Stimulation During Esophagectomy

Start: Nov 2019Est. completion: Oct 202014 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.